Kristin, you, everyone. morning, good and Thank
Companion across Kristin growth and terms of XX% mentioned, on an of is and basis operational Today, grew I our our with decline the the in livestock full largely products year on As quarter. had reported operational of products, guidance. $XXX way X% impact update X% our core performance, we basis. dermatology billion, an on $X other growing from the Librela, an the of first business while products, reported other X% X% which Of provide growing franchises. and product X% Trio X% our revenue led revenue year a and a new operational in includes on China. swine performance X% generated from very a result X% continued of products number in start an price of quarter, X% first consisted in-line of species the from income financial X%. to contributing on the animal volume. basis. Simparica strong X% Volume my to focus million was the growth, comments In X% key with net growth a and key drivers to a difficult the on prior on and basis on and quarter declined The Adjusted comparison of declining products operationally basis year the we in growth, our operational XXXX expected will in-line
XX% our parasiticide we where of million in number the recently was revenue also meaningfully growth Our osteoarthritis and QX, XX% posted contributed in antibody terms growth animal operationally. revenue, dogs, the a $XX sales. heartworm Simparica and representing which $XXX growth for derm innovative the pain posting operational was growth representing key portfolio quarter, dermatology international in growth quarter, of million, quarter. to of first contributor against our of and heartworm had in and largest grew drove one XXXX in again tick portfolio In revenue, is XX% $XXX of launched launched comparable Librela, Trio global diverse Europe, our global canine Trio growth Japan, with which market. prior U.S. Simparica in period. products, sizable key Apoquel small year the in fleas, robust the versus million parasiticide Cytopoint, in XX% a to recently the monoclonal in operational Trio In Meanwhile, significant sold the
recorded largely new and growth by consumable globally international and Diagnostics of segments. million $XX driven usage XX% in had our was revenue QX, both in growing Global and portfolio across operational Our U.S. sales Growth products.
also a remains and and key is quarter. antibody, $XX the XX% to significant recently monoclonal which in pain million driver in also to Europe, contributed quarter, to We dogs, devices for our first continue in new placement the international Zoetis, growth growth Diagnostics in osteoarthritis for make In in posting see sales. investments in field reference continue new growth force, meaningfully the in grew of our launched technologies markets. we umbrella,
portfolio segments. globally Growth was in had growing sales Diagnostics of and and QX, Global revenue usage U.S. across million both largely in driven operational consumable recorded international Our XX% by our new $XX products. growth and
continue key and to new significant also and our new of remains force, in technologies investments international a we Zoetis, make the continue reference driver see placement for growth lab. markets. devices growth We in field Diagnostics in to
seeing levels our at U.S. care products. million prior more from revenue sales higher of Growth U.S., think grow increase growing I Simparica better the driven by portfolio in the growth to animal above to through Trio was with demographics, dermatology parasiticide well in XX%. were key innovation, the COVID of to $XXX standard what as quarter veterinary was pets. as as again and of compliance sales strong continue in Companion continues we largely the will
with dermatology continue runway material with We within XX% growth. million penetration clinic meet were each on and clinics satisfaction our APOQUEL and is to key sales for products the contributing to for XX% Federal individual take growing significantly Capon approximately and share $XXX quarter, future additional targets growth. revenue
experienced This impacted expected to well primarily a products. last generic care continues producer field quarter, same continuing have dedicated sustainable to to the as the expand in sources animal companion animal our and April, costs our long-term growth in our Jackson, our profitability. from force weigh Meanwhile, of competition approximately patients as year exist resulting support go-to-market remain representing declined which alternatives invest we instrumental support portfolio portion launched creating to diagnostic XX% quarter an quarter from of elevated be Swine the clinic, the favorable we in from as for market. business an result dermatitis in was pharma expanded cattle In U.S. meaningfully didn't of resulting new all the business. large as In to been by more undertreated, pet by from input and portfolio. negatively the to for as space as the of reduced a opportunity with we on challenges for upholstery disease effort for portfolio into expanding smaller U.S. foxises well livestock separate Zoamix. in and of coverage grew XX% will in of strategy, our further pressure our dolls competition equivalence. sales generic cost disease and producers and investment continue higher Our driving use this lower market conditions as companion products
antibodies and International reported with parts brands these and the to Increased quarter. revenue grew continue key benefit products ore dermatology operationally our from Europe, in prospects revenue companion and excited pain sales animal where products, on a America for our growth of direct-to-consumer of on and of international of operationally. and portfolio. revenue declined from grew in alleviation campaigns XX% we operationally, the Moving parasite of to Latin programs. X% our animal Semak our remain X% the Companion segment, X% long-term basis livestock resulted monoclonal
Librela encouraged track pain first million remains performance our delivering are of to sales. million monoclonal million We OA on Cerencia Librela revenue antibody exceed in generating the year. $XX for quarter in $XXX $X with and this by
to and quarter, favorable XX%. metrics our for product in first performance X% Librela rates around market last the one exceeded quarter. the of on growth. being opportunity driven pain dogs became the Meanwhile, As international EU the remain of percentage being with pain Meanwhile, the a expand significant Compliance to a market. the was operationally expand with on percentage launch, declined future meaningful our livestock mentioned the expectations, X% continue the we quarter. livestock swine Librela the dogs predominantly China. number opportunity new pain Librela at in being to Reordering This in decline new initial meaningful international operationally portfolio in year underlying by a market very market. the to declined of in we'll with
a in over As producer increased we impacts past market pork significant prices, months, the in the decline indicated profitability. which several supply port like to
high. addition, our that quarter a presented of period pricing In been first XXXX difficult an had quarter comparative as in all-time and producer at profitability
While was poultry in back for anticipate quarter and we return growth fish, expect year, China offsetting portfolio. to portfolios. in our of in swine our growth Partially the the our a challenging decline swine half second cattle to we
this SRS markets Brazil emerging cattle grew the pricing quarter, product China. markets growth market and well as Turkey generation portfolio of fish in of and vaccine due Our Australia in such products and and as double grew efforts in again to demand for driven favorable AlphaGeLivVac digits Chile. AlphafluxCLIce Sales key as by conditions treatment in
grew tax million. with mix in discrete quarter. tax changes EPS for on adjusted quarter moving were earnings. items a as adjusted expenditures favorable slightly rate Capital as of of operationally adjusted P&L rest the of quarter. certain the of of the increased offset net XX.X%, the operationally R&D operationally by direct-to-pet The authorities, X% key impact and quarter brands. to Adjusted campaigns grew and XX.X% the margin compensation for Now improved gross the to by $XXX jurisdictional expenses the X% was finally, promotion owner driven Advertising XX decrease points, for X% basis first tax and income effective And well due higher costs. settlements in for diluted the
and anticipating significant related of $XXX quarterly dividends. China In long-term still primarily capacity are a largest and over shares, meet manufacturing repurchase share demands. increase our to in combination to dollar-based for approximately ever. million expenditures support $X.X We full repurchases representing of share returned the we Ireland, investments billion through our to shareholders Zoetis We purchased in a quarter, capital the year growth to U.S. XXXX, the needed
for on moving Now XXXX. year guidance to full the
exchange that rates exchange our the dollar. only growth and as rates Please guidance updated guidance. directly revenue of and are the XX% to previous late foreign strengthening that our operational of and XX% for February of as to X% are full April the reflect any ranges to year XX% income note guidance of our U.S. Foreign remained adjusted update and to same related of recent on our the
We are strength companion negatively Beginning range are growth high foreign both We offset Russia animal operational feel full in of operational full revenue impact expected with can we and the $XXX our by million portfolio. despite conflict year growth same Ukraine, the the this holding by with rates bottom to these we of year the of and the the top impacting end low and reflect X%. XXXX, our the for decreasing impact line exchange.
revenue the end while of to billion are the can line reflect of We expected and full year despite full XXXX, billion rates we with this feel year of maintaining portfolio. companion X% the expected conflict low the strength projecting revenue and by now growth We Russia decreasing to $X.XXX of exchange. for the we impact the growth by operational both animal Beginning $X.XXX our our the range between foreign of in and impact high $XXX X%. same with and Ukraine, bottom our impacting negatively operational offset growth million are operational XX%.
while $X.XX of to now $X.XXX and maintaining X% of billion projecting our growth operational XX%. expected between billion We are revenue
expected animal of $X.XX. our the be EPS now expected in diagnostics. of adoption the silicide we the be and And is with key primary continued growth adjusted $X.XX $X.XX diluted $X.X of of year monoclonal pain billion, point-of-care products, reported $X.XX to adjusted further growth expect growth net our range adjusted expansion driver of EPS our For XX%. strength XXXX diluted Sales in companion to to the will OA operational billion of prior to to finally, dermatology the be income to be maintaining in diverse XX% antibodies the portfolio, of range products $X.XXX range of in our income and to the for for while -- net in
for We also companion continue global animal see a favorable to very XXXX. backdrop
animal remain make XXXX. which trends, business more growth macro normalized fundamental believe occur the livestock, protein and in will essential on we For intact,
represents some the year, the XXXX. full of of like on expectations for remainder guidance our would our phasing I While expected to for provide color growth the
expect We activities. business for growth operational certain QX top line below today be and to QX slightly chain supply as
similar a QX where we revenue expect foreign negatively impact also by that We about exchange in in was impacted QX, experienced reported X%.
will In future drive to profitability OpEx revenue significant half revenue, than bottom impacting the the rate in are of making more in QX expansion year field early than growth, faster in a at investments materially the QX year. back and U.S. including we growth the the support DTC force advertising incremental in line addition,
exchange about the of to We will X%. bottom negative line foreign a expect impact QX that in have
full year than Our XXXX the with revenue. or growing adjusted income of and reflects line faster proposition growing than guidance faster once value net in again our market revenue
and of growth, across brands continue our markets and market foreseeable driven of from capitalize to favorable agile We derived dynamics end our dimensions for diversified and develop to business globally. is extract execute and expand success enduring to infrastructure multiple innovation on future. our Our engine in-line multiple and disciplined the of by portfolio sources
your things line operator for over open questions. I'll the hand to the Now to
